Soleno Therapeutics (SLNO) Interest Expenses (2013 - 2026)

Soleno Therapeutics (SLNO) has 14 years of Interest Expenses data on file, last reported at $27.2 million in Q1 2026.

• On a quarterly basis, Interest Expenses rose 1902.13% year-over-year to $27.2 million in Q1 2026; TTM through Mar 2026 was $27.2 million, a 2172.64% increase from a year earlier, with the FY2025 full-year figure at $79.9 million, down 4.31% from the prior year.
• Interest Expenses for Q1 2026 stood at $27.2 million, up from $1.2 million in the prior quarter.
• Over the last five years, Interest Expenses for SLNO reached as high as $170.6 million in Q2 2025 and fell as low as -$264000.0 in Q4 2023.
• Historically, Interest Expenses has averaged $39.2 million across 5 years, with a median of $1.4 million in 2025.
• Across the five-year window, Interest Expenses tumbled 100.46% in 2023 and jumped 13182982.71% in 2024, its largest moves.
• Year by year, Interest Expenses stood at $57.0 million in 2022, then sank by 100.46% to -$264000.0 in 2023, then surged by 93.56% to -$17000.0 in 2024, then surged by 7264.71% to $1.2 million in 2025, then jumped by 2137.19% to $27.2 million in 2026.
• Per Business Quant data, the three most recent Interest Expenses figures were $27.2 million in Q1 2026, $1.2 million in Q4 2025, and $113.6 million in Q3 2025.